A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-7680 in Patients With Hepatitis C Infection
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2015
At a glance
- Drugs MK 7680 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 24 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 31 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 02 Feb 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.